Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Other Accumulated Expenses (2019 - 2026)

Angiodynamics' Other Accumulated Expenses history spans 13 years, with the latest figure at $4.7 million for Q1 2026.

  • For Q1 2026, Other Accumulated Expenses fell 19.09% year-over-year to $4.7 million; the TTM value through Feb 2026 reached $4.7 million, down 19.09%, while the annual FY2025 figure was $7.4 million, 2.51% down from the prior year.
  • Other Accumulated Expenses reached $4.7 million in Q1 2026 per ANGO's latest filing, down from $6.7 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $10.3 million in Q1 2024 to a low of $1.8 million in Q4 2023.
  • Average Other Accumulated Expenses over 5 years is $5.0 million, with a median of $4.7 million recorded in 2026.
  • Peak YoY movement for Other Accumulated Expenses: soared 408.79% in 2024, then crashed 43.88% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $2.6 million in 2022, then tumbled by 31.83% to $1.8 million in 2023, then skyrocketed by 408.79% to $9.0 million in 2024, then decreased by 25.08% to $6.7 million in 2025, then crashed by 30.68% to $4.7 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Other Accumulated Expenses are $4.7 million (Q1 2026), $6.7 million (Q4 2025), and $8.7 million (Q3 2025).